Alterations in 5-hydroxytryptamine (5-HT) signaling have been implicated as a factor contributing to the altered bowel habit of irritable bowel syndrome (IBS) patients. Tryptophan hydroxylase 1 (TPH1) is the rate-limiting enzyme in enterochromaffi n cell 5-HT biosynthesis. We hypothesized that genetic variants affecting TPH1 gene expression might alter intestinal 5-HT bioavailability and subsequently the propensity for distinct bowel habit subtypes in IBS. In this study, we assessed the only common TPH1 proximal promoter variant ( − 347C / A; rs7130929) and its association with bowel habit predominance in IBS.
INTRODUCTION
Abnormalities in serotonin (5-hydroxytryptamine (5-HT)) signaling have been implicated in irritable bowel syndrome (IBS) pathogenesis. When induced by luminal chemical and mechanical signals, enterochromaffin (EC) cells release 5-HT, which stimulates 5-HT 3 and 5-HT 4 receptors on primary afferent neurons, to induce peristaltic and secretomotor reflexes that regulate intestinal motility and secretion ( 1 ) . In patients with diarrhea-predominant IBS (IBS-D), platelet-depleted postprandial plasma 5-HT concentrations are higher compared with patients with constipation (IBS-C) and healthy controls ( 2,3 -5 ) , while IBS-C patients have a mitigated postprandial rise in plasma 5-HT compared with controls ( 3, 6 ) . Plasma 5-HT is almost exclusively derived from the gut EC
Identifi cation of a Functional TPH1 Polymorphism Associated With Irritable Bowel Syndrome Bowel Habit Subtypes

FUNCTIONAL GI DISORDERS
TPH1 SNP and IBS Bowel Habit cells secreting 5-HT, which is not taken up by platelets and overflows into the circulation ( 6 ) . Plasma 5-HT levels also positively correlate with gut motility under both fasting and fed conditions ( 7 ) , suggesting that they parallel the mucosal bioavailability of 5-HT in the intestine. Together, these findings suggest that differences in mucosal 5-HT levels correlate with the IBS clinical bowel habit phenotype. This concept is indirectly supported by the beneficial effects of 5-HT 4 receptor agonists in IBS-C and 5-HT 3 antagonists in IBS-D ( 8 ) .
One factor that could modulate mucosal 5-HT availability is the activity or expression of the 5-HT selective reuptake transporter (SERT), which terminates bioamine action and prevents receptor desensitization by removing 5-HT from the interstitial space. Although SERT mRNA is widely expressed, the quantities found in the gut epithelium are very low, particularly in the colon. Th us it may not be surprising that confl icting results have been reported concerning colonic SERT mRNA in IBS ( 9 -12 ) .
Conceivably, 5-HT biosynthesis is another process potentially infl uencing mucosal signaling. Tryptophan hydroxylase 1 (TPH1) is the rate-limiting enzyme in the biosynthesis of 5-HT in EC and mast cells. Although both TPH1 and TPH2 are expressed in the gut, TPH2 is expressed by enteric and central neurons, and TPH1 is the predominant enzyme in EC cells ( 13 ) . Although the activity of TPH1 is controlled at multiple levels, including post-translational regulation ( 14 ) , recent evidence from animal studies indicates that changes in TPH1 transcription can aff ect proportional changes in intestinal and plasma 5-HT levels ( 15 ) . TPH1 is therefore an intriguing candidate gene for conditions with altered 5-HT bioavailability as proposed for the distinct bowel habit subtypes in IBS.
Th is idea is the basis for the development of an oral TPH1 inhibitor acting locally on the gastrointestinal (GI) mucosa ( 15 ) . A recent phase II clinical trial demonstrated the effi cacy of this novel compound in relieving symptoms of non-constipating IBS ( 16 -18 ) . Th e clinical response to therapy correlated with a decrease in 24-h urine excretion of the metabolite 5-hydroxyindoleacetic acid refl ecting reduced 5-HT biosynthesis, which is promising particularly as there is currently a lack of established biomarkers to predict treatment response in IBS.
We recently identifi ed the murine Tph1 homolog as a target of the zinc fi nger transcription factor ZBP-89 (ZNF148) ( 19 ) . Evaluating putative ZBP-89 binding sites in the human TPH1 promoter, we observed that a common single-nucleotide polymorphism (SNP) adjacent to a GC-rich sequence motif altered DNA binding of nuclear proteins to this site. We hypothesized that this promoter variant could aff ect the amount of 5-HT generated by the EC cells via a gene dosage eff ect and thus modulate the susceptibility to distinct bowel habit phenotypes in IBS. Here we report that this − 347C / A promoter SNP (rs7130929) diff erentially binds early growth response factor 1 (EGR-1) in vitro and associates with bowel habit subtypes in IBS patients.
METHODS
Human study subjects
Male and female IBS patients and healthy control subjects, who were at least 18 years of age and participating in clinical research studies or were being evaluated in the gastroenterology clinic at two metropolitan university medical centers, were consecutively recruited to provide saliva or blood samples for DNA analysis. For the colonic biopsy study, IBS patients and healthy controls between the ages of 18 and 55 years were recruited at one of the centers, although subjects were not consecutively enrolled. Th e diagnosis of IBS and bowel habit subtyping was determined by the Rome III criteria ( 20 ) , the absence of other chronic GI conditions that could explain IBS symptoms, and by a clinician with expertise in IBS. Healthy control subjects were recruited by advertisement and did not have a history of IBS, abdominal surgeries other than an appendectomy, cholecystectomy, or hysterectomy without residual GI symptoms, or other chronic GI or pain conditions, and were not taking psychotropic medication or participating in psychotherapy. Th e controls did not meet IBS bowel habit subtyping criteria for diarrhea, constipation, or mixed pattern (i.e., they did not have > 25 % hard / lumpy or loose / watery stools). Validated questionnaires were used to assess IBS symptoms. Depression and anxiety symptoms were measured using the Hospital Anxiety and Depression scale ( 21 ) at one center and the Beck Depression and Anxiety scales at the other ( 22, 23 ) . Subjects were compensated for their participation in the study. Th e Institutional Review Boards at both study sites approved this study and informed consent was obtained from all subjects.
Genotyping
Blood or saliva samples (Oragene DNA Self-Collection Kit; DNA Genotek, Ottawa, Ontario, Canada) collected for DNA extraction at Washington University were frozen and banked in the BioBank Core of the Digestive Diseases Research Center. DNA was extracted using the Qiagen Gentra Puregene Reagents (Qiagen, Valencia, CA), and genotyping was performed using Sequenom MassARRAY Technology (Sequenom, San Diego, CA) in a single batch containing all of the study samples (cases and controls). Th e laboratory staff was blinded to both the study subject group assignment and the study hypotheses. DNA samples were also collected from a total of 575 subjects (IBS patients and controls) at the UCLA site. Saliva samples were collected in Oragene DNA Collection Kits at the UCLA Center for Neurobiology of Stress. UCLA Biological Samples Processing Core extracted DNA from the saliva samples using the Autopure LS Nucleic Acid Purifi cation instrument (Gentra Systems, Minneapolis, MN). Eight percent were excluded due to low amounts of DNA or subjects declining to share samples. DNA was sent to the University of Michigan for genotyping, which was successfully completed in 99.6 % of samples. For genotyping of the − 347C / A (rs7130929) variant by restriction fragment length polymorphism, a 484-bp fragment was amplifi ed by hotstart PCR (Qiagen) with the following primers: forward -5 ′ -CTGCGTGTATCTGACTGGT GT-3 ′ and reverse -5 ′ -GGGATAAGGAGCTAATCG-ACTGA-3 ′ , digested with Msl I restriction enzyme (New England Biolabs, Ipswich, MA; Invitrogen, Carlsbad, CA), and then separated on 2 % agarose gels. Only amplicons from the A-allele were cut by Msl I into 207-and 277-bp fragments. Th e extended human TPH1 promoter region ( 24 ) was ampli fi ed using the Platinum
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Taq DNA polymerase (Invitrogen) and oligonucleotide primers 5 ′ -CTGCGTGTATCTGACTGGTGT-3 ′ and 5 ′ -GAAAGGTCTCT CCCTGACCA-3 ′ in subsets of the IBS and control populations. Amplicons were sequenced bidirectionally at the University of Michigan DNA Sequencing Core.
Measurement of TPH1 mRNA in colonic biopsies
Flexible sigmoidoscopy to at least 40 cm from the anal verge was performed in the UCLA Medical Procedures Unit. Subjects were instructed to use two tap-water enemas as the bowel preparation. During the sigmoidoscopy, sigmoid colon biopsies were taken at 30 cm from the anal verge and immediately snap frozen in liquid nitrogen to avoid RNA degradation before tissue extraction.
Total RNA was isolated from non-pooled colonic biopsies and cDNA generated by reverse transcription (Applied Biosystems, Foster City, CA). Real-time PCR amplifi cation was performed on a 7500 FAST Real-Time PCR System (Applied Biosystems) using Fast Universal PCR Master Mix and validated fl uorogenic TaqMan probe sets (Applied Biosystems) for TPH1 (Hs00188220_m1) and 18S-rRNA (Hs99999901_s1). Relative expression of TPH1 was normalized to 18S-rRNA. Duplicate sample analysis for each patient showed excellent correlation throughout the study group.
Electrophoretic mobility shift assay (EMSA)
As the rs7130929 SNP resided within the proximal promoter of the TPH1 gene where transcription factors can bind, EMSA protein -DNA binding assays were performed. Protein extracts from nuclei of the human 5HT-producing BON cell line were prepared essentially as previously described ( 25 ) . Th e concentration of total nuclear protein determined colorimetrically using the bicinchoninic acid method (BCA assay; Th ermo Fisher Scien tifi c, Waltham, MA). To prepare the EMSA probes, the two allele-specifi c pairs of gel-purifi ed complemen tary oligonucleotides corresponding to the − 361 to − 326 region of the TPH1 promoter (5 ′ -CAGAAGCACAGAGA(g / t)GTGTGGGAG GTGGGGGGATTC-3 ′ ) were end labeled with radioactive 32P using T4 polynucleotide kinase. Duplex DNA assembled by annealing of the 32 P-labeled complementary oligonucleotides was purifi ed on G50 spin columns. Th e specifi c competitor DNAs were prepared by annealing the unlabeled oligonucleotide pairs. Binding reactions contained 0.5 pmol probe, 2 μ g nuclear protein extract, 0.5 μ g sonicated salmon sperm DNA, and 0.5 μ g poly (dI-dC) (Sigma-Aldrich, St Louis, MO; Santa Cruz Biotechnology, Dallas, TX) in a total volume of 20 μ l. Th e binding buff er consisted of 20 m M Hepes (pH 7.9), 5 mM MgCl 2 , 50 mM KCl, 100 μ M ZnSO 4 , 0.5 mM dithiothreitol, and 10 % glycerol. Aft er incubation (10 min at room temperature followed by 20 min on ice), the samples were loaded onto a 5 % polyacrylamide gel (acrylamide:bis-acrylamide 37.5:1) and separated at 10 V / cm in 0.5 × TBE (45 mM Tris base, 45 mM boric acid, 1 mM EDTA). Dried gels were analyzed by autoradiography. For antibody interference, the reaction mixtures lacking the probe were incubated for 20 min on ice with antibodies against Sp1 (clone H225), Sp3 (D20), EGR-3 (C-24), EGR-1 (rabbit polyclonal 588), GATA-1 (N6; all from Santa Cruz Biotechnology), or ZBP-89 ( 26 ) , before addition of the probe and further processing as above. For competition experiments, unlabeled competitor DNAs in 100-fold molar excess over the labeled probe were included in the binding reactions.
Luciferase reporter assays
To test the function of the two SNP alleles in the 5-HT-producing BON cell line, the − 568 / + 19 promoter region of the human TPH1 gene was amplifi ed by PCR using the forward primer 5 ′ -TATGG-TACCTTTGGGATAAGGAGCTAATCGA-3 ′ and the reverse primer 5 ′ -TATCTCGAGTAGGTGCAGGCTGGGTCG-3 ′ from genomic DNA of subjects homozygous for either the A-or C-allele of rs7130929. Th e two products were cloned directionally into the promoterless luciferase reporter vector pGL3-basic (Promega, Madison, WI) to generate − 347A-Luc and − 347C-Luc, respectively. Both constructs were confi rmed by sequencing.
BON cells were grown in 24-well plates to 90 -95 % confl uence and transiently transfected in triplicate with 0.25 μ g / well of the TPH1 reporter constructs using Lipofectamine 2000 transfection reagent (Invitrogen) diluted in serum-free OptiMEM I. Twenty ng / well of the pRL-Tk plasmid (Promega), expressing Renilla luciferase from a thymidine kinase promoter, was co-transfected as an internal control. Th e medium was replaced by fresh DME / F-12 8 h following transfection. To evaluate the eff ect of EGR-1 overexpression, cells were co-transfected with 0.2 μ g / well of a human EGR-1 expression vector (Origene, Rockville, MD) or the empty pCMV6 vector as the control, and luciferase activity was measured 24 h post transfection. In EGR1 knockdown experiments, BON cells were co-transfected with either 20 pmol / well of EGR1 siRNA (Silencer Select s4538; Invitrogen) or scrambled control siRNA (control siRNA No. 2; Invitrogen). Twenty-four hours following transfection with siRNA, the cells were stimulated for 4 h with 200 n M 12-O -tetradecanoylphorbol-13-acetate (TPA) before assaying for luciferase activity.
Western blotting
BON cells were homogenized in lysis buff er (50 mM Tris / HCl (pH 8.0), 150 mM NaCl, 0.1 % sodium dodecyl sulfate, 0.5 % sodium deoxycholate, 1 % NP40) containing a protease inhibitor cocktail (Roche, Indianapolis, IN). Fift y micrograms protein / well were separated on 4 -20 % SDS-polyacrylamide gradient gels under reducing conditions and blotted to PVDF (polyvinylidene difl uoride) membranes. Blots were probed with anti-EGR-1 (S-25, Santa Cruz Biotechnology) and anti-GAPDH (MAB374 , EMD Millipore, Billerica, MA).
Statistical analysis
Th e two subject groups (UCLA, Washington University) were combined in the analysis. As current anxiety and depression symptoms were measured using two diff erent validated questionnaires at the two study sites, we calculated Z -scores for anxiety and depression aft er combining the subject groups.
Hardy -Weinberg equilibrium was tested for the TPH1 SNP (at − 347; rs7130929). All three genetic models were evaluated for the TPH1 SNP (additive, dominant, and recessive; where FUNCTIONAL GI DISORDERS TPH1 SNP and IBS Bowel Habit recessive was coded as homozygous for the major C-allele vs. the other genotypes). An additive eff ect genetic model was tested among IBS cases and controls using a Cochran -Armitage test for trend. Th e dominant and recessive models were tested among IBS and controls using a Chi-square test. We utilized multinomial logistic regression models to determine the relationship between the TPH1 rs7130929 SNP with the odds of having a certain bowel habit within the IBS group and while controlling for potential confounders, including race / ethnicity, study site, and psychological symptoms (e.g., anxiety and depression symptoms), that diff er between IBS bowel habit subgroups. Goodness of fi t was evaluated using a test of deviance. We chose to control for psychological symptoms, because a recent study showed that a TPH1 SNP (rs4537731) was associated with psychological distress ( 27 ) . In addition, we only modeled using IBS-C, IBS-D, and IBS-M patients as there were only 12 IBS-U patients and 6 IBS patients with missing bowel habit data. Th erefore, the outcome consists of three nominal categories (IBS-C, IBS-D, and IBS-M, with IBS-C as the reference group).
Adjusted odds ratios and corresponding 95 % confi dence intervals (CIs) were reported from the models. TPH1 mRNA data were log-transformed to achieve approximate normality and geometric means. Th e 95 % CI were reported. A two-sample t -test was used to compare TPH1 mRNA expression between IBS cases and controls, analysis of variance was used to compare TPH1 mRNA levels across bowel habit, and the Spearman ' s correlation was used to compare gene expression across additively coded TPH1 genotypes. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) or R version 2.15.1 ( http://cran.r-project. org/ ). Signifi cance was assessed at the 0.05 level.
RESULTS
Allele-specifi c nuclear protein binding to proximal TPH1 promoter variant
As we recently discovered that transcription factor ZBP-89 regu lates the mouse Tph1 promoter ( 19 ), we analyzed the human TPH1 promoter for ZBP-89 consensus regulatory elements. We identifi ed several putative sites in the proximal promoter with one near a biallelic SNP (rs7130929) at position − 347 relative to the transcriptional start site. As the location of the SNP was within the proximal promoter of the TPH1 gene, we considered that the SNP might contain the binding site for transcription factors that bind DNA and modulate gene expression. Th erefore we used EMSAs, a DNA binding assay, to evaluate whether nuclear proteins actually bind to the 36 base pair DNA sequence containing the − 347C / A (rs7130929) SNP of the TPH1 promoter and whether the two diff erent alleles modulated protein binding. Th e ancestral allele at this site was " C " and the minor variant (A-allele) occurred with a frequency of 35 % in the general population ( http://www.ncbi.nlm.nih.gov ). Nuclear proteins were extracted from BON cells, a 5-HT-producing human pancreatic carcinoid cell line. We found that radioactive EMSA probes containing either the C-or A-allele at − 347 specifi cally bound three protein complexes ( Figure 1a ). In addition, the EMSA revealed a distinct protein complex that preferentially bound to the A-allele ( − 347A probe). As a GC-rich site fl anked the SNP-containing DNA element, we tested whether zinc fi nger transcription factors accounted for diff erential binding of the protein complexes to the A-allele. Th is was accomplished by adding diff erent antibodies to determine if they disrupted transcription factor binding. Indeed Sp1 and to a lesser extent, Sp3 and ZBP-89, respectively, decreased the intensity of the upper and lower complexes, while there appeared to be little eff ect of the GATA1 antibodies ( Figure 1a , see Supplementary Figure S1 online). However, none of these factors accounted for the novel complex binding preferentially to the A-allele. To further characterize this complex, we examined whether DNA binding was induced by common signal transduction pathways, e.g., protein kinase A, activated by forskolin, or protein kinase C, activated by phorbol esters. We found that the allele-specifi c binding activity was robustly induced in extracts from serum-starved BON cells treated for 1 h with fetal bovine serum (FBS) or phorbol esters (TPA) but not by forskolin ( Figure 1b ) .
EGR-1 binds differentially to TPH1 − 347 SNP site and modulates TPH1 promoter activity
As rapid induction by proliferative signals, e.g., FBS and TPA, is a characteristic feature of immediate early genes, we considered the possibility that the novel protein complex binding to the − 347A site would be formed by an immediate, early transcription factor that recognizes GC-rich sequences. Few zinc fi nger transcription factors are known to rapidly increase their binding in response to proliferative signals. However, members of the EGR family of transcription factors are known to meet these criteria. Indeed, EGR-1 but not EGR-3 antibodies completely shift ed the A-allele-specifi c complex confi rming EGR-1 as the nuclear protein ( Figure 1c ) . We demonstrated by western blots that both TPA and FBS stimulate EGR-1 protein expression in BON cells ( Figure 1d ). EGR-1 was robustly induced within 1 h of stimulation, especially with TPA, consistent with increased binding on the EMSAs. Th erefore, the two alleles of the − 347 TPH1 promoter SNP diff erentially bind EGR-1. When we reviewed in silico the extended weight matrix for EGR-1 binding sites, we found that the SNP lies adjacent (position − 1) to a nonameric EGR family recognition site overlapping an Sp1 binding motif ( Figure 1e ). In vitro DNA binding site selection studies indicate a strong preference for adenine at − 1 of the extended EGR-1 binding matrix ( 28 ) , which is consistent with our EMSA results showing preferential binding of EGR-1 to the minor A-allele.
Having established that the common − 347C / A SNP in the TPH1 promoter alters an EGR-1 binding site, we tested whether diff erential binding of EGR-1 can modulate TPH1 promoter activity using a cell line-based reporter assay. Th e human TPH1 ( − 568 / + 19) proximal promoter region ( Figure 1f ) containing either the C-or A-allele at position − 347 was subcloned into a luciferase reporter plasmid and transfected into BON cells. Both the − 347A-Luc and − 347C-Luc reporter constructs drove significant luciferase expression compared with a promoterless control vector ( Figure 1g ). However, there was no signifi cant diff erence at baseline between the promoter activities of the two alleles in BON cells using this type of cell line-based assay. Th erefore, to compare the relative activity of the two alleles at low or high EGR-1 expression levels, an EGR-1 expression vector or siRNA for EGR1 was
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activity of the isolated proximal TPH1 promoter fragment in vitro , our results indicate that modulating EGR-1 binding to the − 347 site could potentially lead to diff erential TPH1 expression in vivo as a function of the two SNP alleles.
Genetic association of − 347C / A (rs7130929) TPH1 variant with IBS bowel habit subtype
To determine whether the − 347C / A TPH1 promoter variant was associated with distinct bowel habit subtypes in IBS, we cotransfected with the TPH1 reporter construct containing either the A-or C-allele. Th e − 347C / A SNP did not alter promoter activity when cotransfected with empty expression vector or scrambled sequence siRNA control ( Figure 1h ). However, when EGR1 expression was suppressed by RNA interference ( siRNA EGR1 ), expression of the A-allele was lower than the C-allele ( P = 0.036; Figure 1g ). Conversely, when EGR-1 was overexpressed, expression of the A-allele was slightly but signifi cantly higher than the C-allele ( P = 0.009). Despite only a modest eff ect of the SNP on the For each experiment and within each treatment group, the relative activity of the minor A-allele was normalized to the activity of the C-allele (set to 100 % ). Each bar represents mean ± s.e. from three independent experiments performed in triplicate transfections. * P < 0.05. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. ( Figure 2 ) indicating that the − 347C / A SNP was not a risk factor for IBS. When comparing the TPH1 genotype frequencies between the IBS bowel habit subgroups, the IBS-U group was excluded because there were too few samples ( n = 12, 3 % ). Th e dominant, recessive, and additive coding of the rs7130929 TPH1 SNP were evaluated in a multinomial regression model predicting bowel habit while controlling for race / ethnicity, and the recessive model was found to yield the lowest P -value. Th us, we focused on the recessively coded TPH1 SNP in the following results. Th e prevalence of the CC genotype was signifi cantly diff erent across all the three IBS bowel habit subgroups ( P = 0.016). Th ere was a signifi cantly greater prevalence of the CC genotype in the IBS-D subtype (47 % ) compared with the IBS-C (25 % ) ( P = 0.004) and IBS-M (37 % ) ( P = 0.057) subtypes ( Figure 2 ). Th ese diff erences in bowel habit remained signifi cant in a multinomial regression model predicting bowel habit from TPH1 genotypes controlling for race / ethnicity, anxiety, depression, and study site ( P = 0.039). Th e odds ratio for comparing the prevalence of the C-allele in IBS-D to IBS-C was 2.47 (95 % CI 1.23 -4.95, P = 0.011). Th e odds ratio for comparing the prevalence of the C-allele in IBS-M with IBS-C was 1.77 (95 % CI 0.97 -3.23, P = 0.063). As shown in Figure 2 , the Caucasian group only included non-Hispanic whites as the genotype frequencies for Hispanics was shown separately. However, to determine if genotype frequencies diff ered within the Caucasian group, the largest racial group within the study population, we included both Hispanic and non-Hispanic Caucasians to improve power. In the IBS-D subgroup, 42.9, 45.7 and 11.4 % had the CC, AC, and AA TPH1 genotypes. Comparable proportions in the IBS-C group were 23.7, 57.6, and 18.6 % and in the IBS-M were 37.2, 45.0 and 17.7 % . Th e C-allele was more prevalent in the IBS-D group compared with the IBS-C group ( P = 0.015), which was greater than the IBS-M group ( P = 0.046) aft er controlling for anxiety, depression, and study site. Th e prevalence of the C-allele was similar in IBS-D and IBS-M ( P = 0.359). Both regression models (all race / ethnicity and within Caucasian) were evaluated for goodness of fi t and had P -values ranging from 0.69 to 0.71, which indicated no evidence of dispersion. Overall, these results suggested that the − 347C / A (rs7130292) polymorphism in the proximal TPH1 promoter is associated with bowel habit predominance within our IBS population.
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Association of the − 347C / A (rs7130929) TPH1 variant with colonic mucosal TPH1 mRNA
We measured TPH1 mRNA in colonic biopsies obtained from 62 patients with IBS (15 IBS-D, 32 IBS-M, 14 IBS-C, 1 IBS-U) and 50 healthy controls. Th e results were suggestive of higher TPH1 transcript levels in IBS patients compared with healthy control subjects ( Figure 3 ) and specifi cally in IBS-D patients (geometric mean (95 % CI); 610 (224 -1664)) compared with healthy control subjects (358 (267 -481); P = 0.099) as expected. However, within the IBS group TPH1 mRNA levels were not statistically diff erent in patients with the − 347C / C TPH1 genotype (geometric mean (95 % CI); 652 (214 -1990)) compared with those with the − 347C / A (388 (193 -781)) and − 347A / A (398 (32 -5009)) genotypes ( P = 0.615).
DISCUSSION
In this study, we identifi ed a functional variant in the human TPH1 promoter that associates with bowel habit subtype in IBS patients. Th ese results support the role of TPH1 as a candidate gene for conditions with abnormal mucosal 5-HT bioavailability as previously inferred from gene dosage eff ects in animal models ( 15 ) .
In our evaluation of the two alleles comprising the − 347C / A (rs7130929) SNP site for binding to nuclear proteins, we found that EGR-1 preferentially bound to the A-allele sequence along with other zinc fi nger transcription factors, e.g., Sp1, Sp3, and 
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colonic TPH1 expression showed a trend towards higher expression in IBS-D compared with healthy controls, although this diff erence was not statistically signifi cant. In IBS patients, the presence of the − 347A-allele signifi cantly reduced the odds for manifestation of the IBS-D over IBS-C subtype. Overall, these fi ndings suggest that the A-allele reduces TPH1 transcriptional activity compared with the C-allele, at least in the context of IBS. Mean colonic TPH1 mRNA was lower in IBS patients with the CA genotype compared with those with the CC genotype, but this diff erence did not reach statistical signifi cance. Unfortunately, the low number of available colonic biopsies from IBS patients with the AA genotype precluded meaningful comparison with CC homozygotes. In addition, the wide variation in TPH1 mRNA levels suggests that there are other factors (e.g., environmental, dietary) that exert a signifi cant eff ect in addition to the TPH1 genotype. Clearly, future studies in a larger number ZBP-89. Th is fi nding was consistent with in vitro binding site selection studies showing that the − 1 position adjacent to the canonical EGR consensus sequence impacts the affi nity of EGR-1 binding ( 28 ) . Th e diff erential binding of EGR-1 to the − 347 (rs7130929) SNP suggested that the SNP could modulate DNA regulatory protein binding, TPH1 expression, and ultimately 5-HT production. Recent studies support the notion that diff erences in 5-HT bioavailability in the colon might correlate with distinct bowel habit subtypes in IBS patients ( 29 ) . Th erefore, to understand the signifi cance of this SNP in vivo , we examined the allele frequencies in IBS patients in which altered intestinal 5-HT bioavailability appears to be linked to distinct bowel habit phenotypes. We hypothesized that in IBS patients the IBS-D subtype, which has been linked to higher 5-HT bioavailability, would be associated with a transcriptionally more active TPH1 promoter allele. We found that in a small subset of our cohort, 
TPH1 SNP and IBS Bowel Habit of colonic tissue samples in IBS are needed to further substantiate the relationship between the − 347 SNP (rs7130929) and TPH1 expression in vivo . Th e TPH1 − 347 (rs7130929) SNP was not directly associated with the diagnosis of IBS overall. Th is fi nding is consistent with the results of a recent study by Jun et al. showing that in Caucasian female IBS patients the TPH1 − 1066 (rs4537731) SNP, which is in linkage disequilibrium (i.e., highly correlated) with the − 347 SNP (rs7130929) in this racial group (see Supplementary Table S1 online), does not predict IBS status ( 27 ) . Rather, the − 347 SNP (rs7130920) predicts bowel habit predominance. However, Jun et al. found that patients who were homozygous for the minor allele of the − 1066 SNP had a higher severity in daily diarrhea symptoms compared with the other two genotypes, but there were no diff erences in bowel habit subtype. Th ese results diff er from those in our study, although there are methodological diff erences. Our subject groups had diverse racial / ethnic backgrounds and were not comprised of only Caucasians as in the Jun et al. study. Although we cannot make conclusions about the association of the TPH1 SNP and IBS-D vs. IBS-C within each racial group due to the relatively small sample sizes, this association was signifi cant within the Caucasian group. Another methodological diff erence is that we did not measure daily IBS symptoms. Furthermore, in the Jun et al. study, the bowel habit subtypes were classifi ed using the Rome II criteria (personal communication, Jun and Heitkemper), while we used the Rome III criteria. Th e Rome II bowel habit subclassifi cation criteria ( 30 ) categorizes only IBS-D and IBS-C based on a combination of abdominal and bowel symptoms (including stool form). In contrast, the Rome III bowel habit subclassifi cation criteria ( 20 ) identify IBS-D, IBS-C, IBS-M, and IBS-U (unsubtyped) based solely on the prevalence of stool form types. Th e Rome II and III bowel habit subtype classifi cations are based on recall of the prevalence of the GI symptoms over the past 3 months and do not require prospective daily stool diaries ( 9 ) . Th us, there can be poor agreement between the Rome II and Rome III subtyping of IBS bowel habits ( 31 ) . In our study, we showed that patients who were homozygous for the major allele of the − 347 (rs7130929) SNP were more likely to have IBS-D vs. IBS-C. Similarly, IBS-D patients were more likely to have the major allele of the − 1066 (rs4537731) SNP vs. IBS-C in our IBS patient population ( P = 0.07). Th us, the diff erences in our studies are likely due to methodological diff erences in symptom assessment and bowel habit classifi cation. Perhaps, objective measures of stool frequency and consistency and GI transit would have correlated better with TPH1 genotype and mRNA levels.
In summary, we have identifi ed a proximal TPH1 promoter SNP (rs7130929) that segregates with stool consistency in a patient population with IBS (i.e., greater CC genotype frequency in the IBS-D subgroup). Th is variant diff erentially aff ects binding of the transcription factor EGR-1, an early response gene product that potentially modulates TPH1 gene expression in the context of the − 347 (rs7130929) A-allele. As a result, the SNP genotype appears to correlate with TPH1 expression in vivo and could have a valuable role in predicting an IBS patient ' s response to medications targeting the 5-HT signaling system, including the recently developed TPH-1 antagonists ( 16 ). 
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